SCHEMBL21045114

SCHEMBL21045114

CC(=O)N1CCC[C@H]1C(=O)NCCCc1ccc(-c2ccccc2F)cc1

nearest known ligand 0.57

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 13/20 0.57
DPP4 P27487 1/20 0.46
POLB P06746 1/20 0.46
P2RX7 Q99572 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21045115 1.00 FKBP1A (0.57) FKBP1ADPP4POLBP2RX7
SCHEMBL29411452 1.00 FKBP1A (0.57) FKBP1ADPP4POLBP2RX7
SCHEMBL21100601 0.87 FKBP1A (0.44) FKBP1APOLBP2RX7
SCHEMBL21100499 0.87 FKBP1A (0.44) FKBP1APOLBP2RX7
SCHEMBL21045499 0.80 ALDH1A1 (0.48) POLB
SCHEMBL29411602 0.80 ALDH1A1 (0.48) POLB
SCHEMBL8104234 0.79 POLB (0.65) FKBP1APOLB
SCHEMBL8102664 0.75 FKBP1A (0.64) FKBP1APOLB
SCHEMBL21045324 0.75 NAMPT (0.48) POLB
SCHEMBL29411378 0.75 NAMPT (0.48) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220089539-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2022-03-24 US disclosed
US-20220089539-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2022-03-24 US disclosed
US-11040945-B2 Tubulin inhibitors LIN BIOSCIENCE PTY LTD. 2021-06-22 US disclosed
US-11040945-B2 Tubulin inhibitors LIN BIOSCIENCE PTY LTD. 2021-06-22 US disclosed
WO-2019113242-A1 TUBULIN INHIBITORS Lin BioScience, LLC (US) 2019-06-13 WO disclosed
US-20190169127-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2019-06-06 US disclosed
US-20190169127-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2019-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089539-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB FKBP1A 2316/4885DPP4 3794/4885POLB 350/4885
US-11040945-B2 Tubulin inhibitors TUBB3, TUBB1, TUBB FKBP1A 2316/4885DPP4 3794/4885POLB 350/4885
US-20190169127-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB FKBP1A 2316/4885DPP4 3794/4885POLB 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.